Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
71
-
Total 13F shares, excl. options
-
51.1M
-
Shares change
-
-4.8M
-
Total reported value, excl. options
-
$16.2M
-
Value change
-
-$1.54M
-
Put/Call ratio
-
0.48
-
Number of buys
-
23
-
Number of sells
-
-41
-
Price
-
$0.32
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2022
94 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2022.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 71 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.1M shares
of 236M outstanding shares and own 21.63% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.2M shares), ACADIAN ASSET MANAGEMENT LLC (7.48M shares), Alerce Investment Management, L.P. (4.65M shares), BlackRock Inc. (4.29M shares), MILLENNIUM MANAGEMENT LLC (3.48M shares), RENAISSANCE TECHNOLOGIES LLC (3.02M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.04M shares), FEDERATED HERMES, INC. (1.8M shares), GEODE CAPITAL MANAGEMENT, LLC (1.62M shares), and FMR LLC (617K shares).
This table shows the top 71 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.